BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study - Turpie,A.G.; Fisher,W.D.; Bauer,K.A. (J Thromb Haemost, 2005)